A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Pacira BioSciences, Inc., a Delaware corporation, is the holding company for our California operating subsidiary named Pacira Pharmaceuticals, Inc. In March 2007, we acquired Pacira Pharmaceuticals, Inc. from SkyePharma Holdings, Inc. (now Vectura Group Limited, a subsidiary of Molex Asia Holdings, Ltd.), or Skyepharma (the “Skyepharma Acquisition”). In April 2019, we acquired MyoScience, Inc., a privately held medical technology company (the “MyoScience Acquisition”), in November 2021, we acquired Flexion Therapeutics, Inc., or Flexion, a publicly traded biopharmaceutical company (the “Flexion Acquisition”) and in February 2025, we acquired GQ Bio Therapeutics GmbH, or GQ Bio, a privately-held biopharmaceutical company (the “GQ Bio Acquisition”). Unless the context requires otherwise, references to “Pacira,” “we,” the “Company,” the “Registrant,” “us” and “our” in this Annual Report refers to Pacira BioSciences, Inc., a Delaware corporation, and its subsidiaries.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 726M | 726M | 701M | 675M | 667M | 542M |
| Net Income | 7.0M | 7.0M | -100M | 42M | 16M | 42M |
| EPS | $0.16 | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 |
| Free Cash Flow | 137M | 137M | 179M | 139M | 115M | 80M |
| ROIC | 0.8% | 1.3% | -7.8% | 5.0% | 5.9% | 12.0% |
| Gross Margin | 79.4% | 79.4% | 75.7% | 72.6% | 70.1% | 74.1% |
| Debt/Equity | 0.60 | 0.60 | 0.82 | 0.68 | 0.99 | 1.07 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 19M | 19M | -73M | 88M | 60M | 90M |
| Operating Margin | 2.6% | 2.6% | -10.5% | 13.0% | 9.0% | 16.6% |
| ROE | 1.0% | 1.0% | -12.1% | 5.1% | 2.1% | 6.2% |
| Shares Outstanding | 44M | 44M | 46M | 47M | 47M | 46M |
Pacira BioSciences, Inc. passes 3 of 9 quality checks, indicating weak fundamentals.
Pacira BioSciences, Inc. trades at 150.4x trailing earnings, compared to its 15-year median P/E of 37.7x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 7.1x vs a median of 22.8x. The company's 5-year average ROIC is 3.3% with a gross margin of 74.4%. Total shareholder yield (buybacks) is 14.0%. At current prices, the estimated annualized return to fair value is +29.1%.
Pacira BioSciences, Inc. (PCRX) has a current P/E ratio of 150.4, compared to its historical median P/E of 37.7. The stock is currently considered Expensive based on its historical valuation range.
Pacira BioSciences, Inc. (PCRX) has a 5-year average return on invested capital (ROIC) of 3.3%. This is below average and may indicate limited pricing power.
Pacira BioSciences, Inc. (PCRX) has a market capitalization of $1.1B. It is classified as a small-cap stock.
Pacira BioSciences, Inc. (PCRX) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 14.02%.
Based on historical P/E analysis, Pacira BioSciences, Inc. (PCRX) appears expensive. The current P/E of 150.4 is 299% above its historical median of 37.7. The estimated fair value CAGR (P/E method) is -23.0%.
Pacira BioSciences, Inc. (PCRX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Pacira BioSciences, Inc. (PCRX) reported annual revenue of $726 million in its most recent fiscal year, based on SEC EDGAR filings.
Pacira BioSciences, Inc. (PCRX) has a net profit margin of 1.0%. This is a modest margin.
Pacira BioSciences, Inc. (PCRX) generated $137 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Pacira BioSciences, Inc. (PCRX) has a debt-to-equity ratio of 0.60. This indicates moderate leverage.
Pacira BioSciences, Inc. (PCRX) reported earnings per share (EPS) of $0.16 in its most recent fiscal year.
Pacira BioSciences, Inc. (PCRX) has a return on equity (ROE) of 1.0%. This indicates moderate shareholder returns.
Pacira BioSciences, Inc. (PCRX) has a 5-year average gross margin of 74.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for Pacira BioSciences, Inc. (PCRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Pacira BioSciences, Inc. (PCRX) has a book value per share of $15.77, based on its most recent annual SEC filing.